Personalised Cancer Vaccine Cuts Risk of Melanoma Returning or Death in Trial

A clinical trial has found that a personalised cancer vaccine, given alongside immunotherapy, reduced the risk of melanoma returning or death by 42 per cent.

The finding concerns the combination of the vaccine and immunotherapy, rather than the vaccine used alone. It points to the potential of personalised approaches to cancer treatment.

The reported reduction measures two outcomes together: recurrence and death. It should not be read as a separate 42 per cent reduction in each, or as evidence that the treatment prevents all cases of relapse.

The trial summary did not specify the number of participants, the length of follow-up or the comparison treatment. Those details are important for assessing the result and what it could mean for people with melanoma.